Drug companies and agents have taken note that from July 1st, large-scale increases will be subject to strong national monitoring.

In fact, enterprises or individual bank account withdrawals, transfers and other large withdrawals are bound to be subject to state surveillance.
July 1st, the large cash management pilot began! Chinese the newly issued "Notice of the Chinese People's Bank on the implementation of large-scale cash management pilot", decided to start in July 2020 in Hebei Province, Zhejiang Province and Shenzhen City to carry out large-scale cash management pilot: 1, the pilot significance for the establishment of large-scale cash management long-term mechanism to lay the foundation, that is, through the three provinces and cities pilot, sum up the accumulation of experience, and then possibly to the whole country.
2, time and place pilot for 2 years, first in Hebei Province, and then extended to Zhejiang Province, Shenzhen.
has been piloting in Hebei Province since July 2020.
starting in October 2020 in Zhejiang Province and Shenzhen.
3, the amount of starting point, three provinces and cities to public accounts (including individual industrial and commercial households to public accounts) cash access of more than 500,000 yuan, Hebei Province to private accounts of more than 100,000 yuan, Zhejiang Province to private accounts of more than 300,000 yuan, Shenzhen to private accounts of more than 200,000 yuan, belong stake in the category of large-scale cash management.
4, large-scale access to register the customer withdrawal, deposit above the starting amount of cash, should be in the processing of business registration.
commercial banks shall also report relevant information to the central branches of the People's Bank of China.
5, cash in kind traceability pilot line to consider the People's Bank of China's crown number data set data set requirements and large cash monitoring requirements, guide banking financial institutions to achieve the starting point above the access business information and cash in-kind crown number associated with traceability.
analysis from the contents of the document, the starting point of the amount includes both a single, but also multiple cumulative, the cumulative period should be a natural day.
management business situation to have cash in-kind transfer of the counter business-oriented, including through large high-speed withdrawal equipment self-service withdrawal situation, and must be for the split, cash hidden accounts and other circumvention of supervision, "pseudo-large cash transactions" situation to develop preventive measures, both to monitor a single transaction over the starting amount, but also to monitor a number of transactions accumulated over the starting amount.
commercial bribery and coupon-free for pharmaceutical companies, CSos and agents! This standard large cash management curbs unreasonable demand, curbs illegal demand, and combats large-scale cash crimes.
because of the characteristics of cash with nameless and untraceable characteristics, large amounts of cash are easy to facilitate corruption, hospital kickbacks, tax evasion and other money-laundering crimes and underground economic activities.
private transfer, cash withdrawal, the boss's private account and the company to the public account frequent capital transactions are facing control, coupled with banks, tax has been shared information, financial institutions and tax departments and other cooperation increased, the medical industry and other departments have also achieved information sharing, private account sedituated funds are easy to be found.
CSO and CSP fund processing schemes are more risky.
hope that through CSO, CSP company, to achieve ticketing, cash, this small trick has long been recognized, the tax department wants to check the operation of enterprises whether there are anomalies, invoice data, tax return data is true, big data will automatically compare analysis, once the detection of dynamic data is not right, low tax burden, the system will automatically alarm.
pharmaceutical companies must not bet on their important marketing behavior to build their own false CSO system, to be sure that the result of this will not only not enhance marketing, more huge financial risks, and ultimately not worth the loss.
in the long run, pharmaceutical companies want to avoid the risks of money laundering, commercial bribery, kickbacks, etc., there is only the last and only way: compliance, compliance academic promotion.
compliance of the real marketing, early to do late, sooner or later to face! National policy continued to hit hard, policies are in reverse the pharmaceutical industry gradually towards compliance, many pharmaceutical companies were fined, the bloody lessons of supervision are still playing out, if still blindly go the old way, it can only be a dead end.
.